56 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships.
Ono Pharmaceutical
Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists.
Ono Pharmaceutical
Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead.
Ono Pharmaceutical
Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists.
Ono Pharmaceutical
Discovery of novel S1P2 antagonists, part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives.
Ono Pharmaceutical
Discovery of highly potent dual EP(2) and EP(3) agonists with subtype selectivity.
Ono Pharmaceutical
Discovery of novel S1P2 antagonists. Part 2: Improving the profile of a series of 1,3-bis(aryloxy)benzene derivatives.
Ono Pharmaceutical
Discovery of a potent, orally available dual CysLT1 and CysLT2 antagonist with dicarboxylic acid.
Ono Pharmaceutical
Discovery of novel S1P2 antagonists. Part 1: discovery of 1,3-bis(aryloxy)benzene derivatives.
Ono Pharmaceutical
Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group.
Ono Pharmaceutical
Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.
Ono Pharmaceutical
Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
Ono Pharmaceutical
Structure-activity relationship studies of S1P agonists with a dihydronaphthalene scaffold.
Ono Pharmaceutical
Discovery of new orally active prostaglandin D2 receptor antagonists.
Ono Pharmaceutical
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.
Ono Pharmaceutical
Structure-activity relationship studies of sphingosine-1-phosphate receptor agonists with N-cinnamyl-ß-alanine moiety.
Ono Pharmaceutical
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.
Ono Pharmaceutical
Design, synthesis, and biological evaluation of novel somatostatin receptor subtype-2 agonists: Optimization for potency and risk mitigation of hERG and phospholipidosis.
Ono Pharmaceutical
Towards a TREK-1/2 (TWIK-Related K+ Channel 1 and 2) dual activator tool compound: Multi-dimensional optimization of BL-1249.
Ono Pharmaceutical
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.
Ono Pharmaceutical
Discovery of a Slow Tight Binding LPA1 Antagonist (ONO-0300302) for the Treatment of Benign Prostatic Hyperplasia.
Ono Pharmaceutical
Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P
Ono Pharmaceutical
Kinase inhibitor, and preparing method and pharmaceutical use thereof
Gan & Lee Pharmaceuticals
D-amino acid oxidase inhibitors and therapeutic uses thereof
SyneuRx International (Taiwan)
Synthesis of a novel series of benzylether-containing cinnamoyl derivatives as histone deacetylase inhibitors.
Shandong University
Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis.
Philipps-Universität Marburg
Active Site Binding Is Not Sufficient for Reductive Deiodination by Iodotyrosine Deiodinase.
Johns Hopkins University
The chlorite dismutase (HemQ) from Staphylococcus aureus has a redox-sensitive heme and is associated with the small colony variant phenotype.
University of Notre Dame
Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
Amgen
Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.
University of Florida College of Medicine
Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (TDP1)- topoisomerase I (TOP1) inhibitors
Purdue Research Foundation
Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
Mei Pharma
Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.
Uppsala University
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
Abbott Laboratories